title: Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer.
abstract: DNA ploidy and S-phase fraction (SPF), determined by flow cytometry were studied in 118 patients with muscle-invasive transitional cell carcinoma (TCC) of the urinary bladder, scheduled for cystectomy after pre-operative radiotherapy (20 Gy/1 week) with or without systemic cisplatin-based neo-adjuvant chemotherapy. The correlation between these parameters and immunohistochemically demonstrated p53, c-erbB-2 and HCG was also investigated. There were 16 DNA diploid and 102 DNA non-diploid tumours. DNA ploidy was not related to the T (all 118 patients) or pN (58 patients) category, occurrence of stage reduction or cancer-related 5 years survival. Patients with high SPF tumours tended, however, to have a better prognosis than those with low SPF TCC reaching the level of significance (P < 0.05) for those patients who had high SPF tumours and received neo-adjuvant chemotherapy. Fifty-one of the tumours were p53 positive. p53 positive tumours were significantly more often found in TCC with low SPFs than in those with high SPFs. Respectively 12 and 9% of the tumours were HCG and c-erbB-2 positive, without correlation to DNA ploidy or SPF. We conclude that DNA ploidy does not represent a prognostic parameter in muscle-invasive operable bladder carcinomas. A high SPF, determined by FCM, may be helpful to identify patients with chemotherapy-sensitive TCC of the urinary bladder.
authors.affiliation: Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
authors.forename: S D
authors.initials: SD
authors.lastname: Fosså
authors.forename: A A
authors.initials: AA
authors.lastname: Berner
authors.forename: A B
authors.initials: AB
authors.lastname: Jacobsen
authors.forename: H
authors.initials: H
authors.lastname: Waehre
authors.forename: B
authors.initials: B
authors.lastname: Kvarstein
authors.forename: T
authors.initials: T
authors.lastname: Urnes
authors.forename: P
authors.initials: P
authors.lastname: Ogreid
authors.forename: T E
authors.initials: TE
authors.lastname: Johansen
authors.forename: J
authors.initials: J
authors.lastname: Silde
authors.forename: J M
authors.initials: JM
authors.lastname: Nesland
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000378:metabolism*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000378:metabolism*; D011003:Ploidies; D018719:Erb-b2 Receptor Tyrosine Kinases; D016196:S Phase; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000532:radiotherapy
chemical_list: D006063:Chorionic Gonadotropin; D009856:Oncogene Proteins, Viral; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53